Q1 FY2027 EarningsKMTS Q1 FY27 results exceeded consensus expectations on the top line and gross margin, though GAAP EPS missed significantly due to a one-time debt extinguishment loss. Revenue of $31.0M (+60% YoY) beat the $29.0M estimate, driven by WCD market expansion and competitive gains. Gross margin reached 56.5%, surpassing the 55.9% consensus. Management raised FY27 revenue guidance to $141M from the previous $137M, signaling continued growth momentum despite widening GAAP losses from commercial expansion.
Financial report interval: 2026.05.01 - 2026.07.31
Overview: Kestra Medical Tech(KMTS) the Revenue is 30.97 M (+59.88%), Beat estimate;the EBIT is -37.66 M (-30.4%), Miss estimate;the EPS is -0.75 (-50%), Miss estimate.
Actual
YoY
Estimate
YoY
Vs estimate
YoY
RevenueExceed expectations
0.03B59.88%
0.03B49.76%
+0.00B10.12%
EBITMiss expectations
-0.04B30.40%
-0.04B24.90%
-0.00B5.50%
EPSMiss expectations
-0.7550.00%
-0.616423.28%
-0.133626.72%
Revenue
ActualEstimateUnit: USD
qf
EBIT
ActualEstimateUnit: USD
qf
Net income
ActualEstimateUnit: USD
qf
EPS
ActualEstimateUnit: USD
qf